Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.53−1.62 (-5.37%)
Close on Nov 12, 2026Market cap $2.24BP/E –Yield –
Celldex Therapeutics statistics
76 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 3.60
- 2.29
Enterprise valuationIndustry
- EV / Sales
- 10064.10
- 2.60
Share statisticsIndustry
- Shares Change (QoQ)
- 0.04%
- 0.51%
- Float
- 78M
- 49M
- Shares Held by Insiders
- 0.41%
- 12.1%
- Shares Held by Institutions
- 109.3%
- 56.4%
Short sellingIndustry
- Short Interest
- 10M
- –
- Short Interest Change
- 3.52%
- -0.76%
- Short % of Float
- 12.7%
- 9.04%
- Short % of Shares Outstanding
- 12.7%
- 6.30%
- Days to Cover
- 10.35
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $45.14
- –
- 52-Week Low
- $22.33
- –
- 20-Day Moving Average
- $29.59
- –
- 50-Day Moving Average
- $32.19
- –
- 200-Day Moving Average
- $32.82
- –
- Average True Range (14)
- $1.52
- –
- Price Change (1 Week)
- 0.92%
- 1.51%
- Price Change (1 Month)
- 2.50%
- -2.35%
- Price Change (3 Months)
- -32.0%
- -21.1%
- Price Change (6 Months)
- -12.1%
- -22.6%
- Price Change (YTD)
- 5.04%
- -22.6%
- Price Change (1 Year)
- 17.1%
- -20.7%
- Price Change (3 Years)
- 5.78%
- -27.4%
- Price Change (5 Years)
- -32.0%
- -77.3%
- Price Change (10 Years)
- -56.0%
- -62.7%
- Average Volume (10 Days)
- 978,331
- –
- Average Volume (20 Days)
- 981,709
- –
- Average Volume (90 Days)
- 1M
- –
- Relative Volume
- 0.70
- 0.79
- Relative Strength Index (14)
- 42.0
- 44.7
- Volatility (1 Year)
- 52.4%
- 80.4%
- Beta (5 Years)
- 1.31
- 1.07
MarginsIndustry
- EBITDA Margin
- -209322.0%
- -27.7%
- FCF Margin
- -164392.0%
- -9.20%
Returns on capitalIndustry
- Return on Equity (ROE)
- -49.5%
- -51.2%
- Return on Assets (ROA)
- -45.1%
- -40.6%
- Return on Invested Capital (ROIC)
- -3698.0%
- -32.9%
- Return on Capital Employed (ROCE)
- -50.6%
- -38.0%
Financial positionIndustry
- Current Ratio
- 10.97
- 3.30
- Quick Ratio
- 10.75
- 2.42
GrowthIndustry
- Revenue Growth (YoY)
- -93.9%
- 7.01%
- Revenue Growth (3Y CAGR)
- -13.1%
- 2.25%
- Revenue Growth (5Y CAGR)
- -26.9%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.00
- 0.40
- Revenue Per Employee
- $798
- $429.29K
- Profits Per Employee
- -$1.56M
- -$683.67K
- Employee Count
- 198
- 75
- WACC
- 11.5%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $650.32M
- $17.46M
- Net Cash Per Share
- $8.28
- $0.72
- Equity (Book Value)
- $649.47M
- $53.27M
- Book Value Per Share
- $8.27
- $1.50
- Tangible Book Value
- $622.28M
- $26.82M
- Working Capital
- $603.22M
- $79.47M
Cash flow (TTM)Industry
- Capital Expenditures
- -$7.77M
- -$944.00K
- FCF Per Share
- -$3.31
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -13.8%
- -20.8%
- FCF Yield
- -11.6%
- -9.58%
Scores and fair valueIndustry
- Altman Z-Score
- 14.17
- 0.30
- Piotroski F-Score
- 2
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLDX | S&P 500 | Difference | CLDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.1% | -2.7% | −0.4 pts | ||
| 3 months | -36.4% | -1.7% | −34.7 pts | ||
| Year to date | +5.0% | +11.9% | −6.9 pts | ||
| 1 year | +17.6% | +12.0% | +5.7 pts | ||
| 3 years | +5.9% | +78.2% | −72.3 pts | +1.9% | +21.2% |
| 5 years | -32.0% | +73.2% | −105.3 pts | -7.4% | +11.6% |
| 10 years | -56.0% | +309.6% | −365.6 pts | -7.9% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
10M CLDX shares were sold short on Oct 30, 2026, up 3.5% from the previous report, or 12.71% of the shares available to trade. At recent volumes it would take 10.3 days to buy them back. Over the last 20 sessions, 62.1% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 9,936,646 | +3.5% | 959,849 | 10.3 |
| Oct 15, 2026 | 9,598,891 | -12.8% | 1,633,453 | 5.9 |
| Sep 30, 2026 | 11,006,720 | +22.9% | 2,886,493 | 3.8 |
| Sep 15, 2026 | 8,953,127 | +3.6% | 682,564 | 13.1 |
| Aug 31, 2026 | 8,641,597 | +14.2% | 706,596 | 12.2 |
| Aug 14, 2026 | 7,569,702 | -0.8% | 954,775 | 7.9 |
| Jul 31, 2026 | 7,627,081 | -0.5% | 1,001,184 | 7.6 |
| Jul 15, 2026 | 7,663,191 | -1.0% | 838,121 | 9.1 |
| Jun 30, 2026 | 7,738,673 | +6.1% | 1,799,211 | 4.3 |
| Jun 15, 2026 | 7,295,393 | +2.1% | 805,783 | 9.1 |
| May 29, 2026 | 7,144,877 | +0.2% | 665,613 | 10.7 |
| May 15, 2026 | 7,130,776 | -6.2% | 708,676 | 10.1 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?